Drug profile · INN
bosentan monohydrate
STAYVEER
bosentan monohydrate (STAYVEER) is a endothelin receptor, et-a/et-b antagonist.
EMA: approved Cardiovascular system (C02) C02KX01
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — bosentan monohydrate
- Class
- Cardiovascular system (C02)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
bosentan monohydrate (STAYVEER) is a endothelin receptor, et-a/et-b antagonist.
Key facts
INN bosentan monohydrate
Brand STAYVEER
Mechanism Endothelin receptor, ET-A/ET-B antagonist
Target Endothelin receptor, ET-A/ET-B
Therapeutic class Cardiovascular system (C02)
ATC code C02KX01
Mechanism of action
Endothelin receptor, ET-A/ET-B antagonist
Primary target: Endothelin receptor, ET-A/ET-B
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is bosentan monohydrate?
bosentan monohydrate (STAYVEER) is a endothelin receptor, et-a/et-b antagonist.
What is the brand name for bosentan monohydrate?
STAYVEER is a marketed brand name for bosentan monohydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.